Phase 3, Cyclophosphamide+Bortezomib+Dexamethasone (CVD), Newly Diagnosed Multiple Myeloma (NDMM), Alkylating Agents, No Cyclophosphamide+Bortezomib+Dexamethasone (NO CVD)
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 3, Cyclophosphamide+Bortezomib+Dexamethasone (CVD), Newly Diagnosed Multiple Myeloma (NDMM), Alkylating Agents, No Cyclophosphamide+Bortezomib+Dexamethasone (NO CVD) 
### Output:
Popular Name is Myeloma XI, Study ID is NCT01554852